Hemostasis in Hypothyroidism and Autoimmune Thyroid Disorders

Authors Information
Article Notes and Dates
To Cite : Ordookhani A, Burman K D. Hemostasis in Hypothyroidism and Autoimmune Thyroid Disorders, Int J Endocrinol Metab. 2017 ;15(2):e42649. doi: 10.5812/ijem.42649.
Copyright: Copyright © 2017, International Journal of Endocrinology and Metabolism. .
Abstract
1. Context
2. Evidence Acquisition
3. Results
4. Overall Conclusions
Acknowledgements
Footnote
References
  • 1. Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med. 2008; 359(9): 938-49[DOI][PubMed]
  • 2. Hulbert AJ. Thyroid hormones and their effects: a new perspective. Biol Rev Camb Philos Soc. 2000; 75(4): 519-631[PubMed]
  • 3. Vescovi PP, Favaloro EJ, Lippi G, Garofano M, Montagnana M, Manzato F, et al. The spectrum of coagulation abnormalities in thyroid disorders. Semin Thromb Hemost. 2011; 37(1): 7-10[DOI][PubMed]
  • 4. Erem C. Coagulation and fibrinolysis in thyroid dysfunction. Endocrine. 2009; 36(1): 110-8[DOI][PubMed]
  • 5. Shih CH, Chen SL, Yen CC, Huang YH, Chen CD, Lee YS, et al. Thyroid hormone receptor-dependent transcriptional regulation of fibrinogen and coagulation proteins. Endocrinology. 2004; 145(6): 2804-14[DOI][PubMed]
  • 6. Doyle JB. Obstruction of the Longitudinal Sinus. Arch Neurol Psychiatr. 1927; 18(3): 374[DOI]
  • 7. Squizzato A, Gerdes VE, Brandjes DP, Buller HR, Stam J. Thyroid diseases and cerebrovascular disease. Stroke. 2005; 36(10): 2302-10[DOI][PubMed]
  • 8. Kaliebe H. Autochthone Sinusthrombose bei einem Falle von Morbus Basedow und Tabes. Med Klin. 1913; 2: 1929
  • 9. Marongiu F, Cauli C, Mariotti S. Thyroid, hemostasis and thrombosis. J Endocrinol Invest. 2004; 27(11): 1065-71[DOI][PubMed]
  • 10. Franchini M. Hemostasis and thyroid diseases revisited. J Endocrinol Invest. 2004; 27(9): 886-92[DOI][PubMed]
  • 11. Franchini M. Hemostatic changes in thyroid diseases: haemostasis and thrombosis. Hematology. 2006; 11(3): 203-8[DOI][PubMed]
  • 12. Erem C, Ersoz HO, Karti SS, Ukinc K, Hacihasanoglu A, Deger O, et al. Blood coagulation and fibrinolysis in patients with hyperthyroidism. J Endocrinol Invest. 2002; 25(4): 345-50[DOI][PubMed]
  • 13. Hofbauer LC, Heufelder AE. Coagulation disorders in thyroid diseases. Eur J Endocrinol. 1997; 136(1): 1-7[PubMed]
  • 14. Ozcan MA, Comlekci A, Demirkan F, Yuksel F, Sari I, Demir T, et al. Plasma levels of free tissue factor pathway inhibitor in patients with various thyroid disorders. Thromb Res. 2003; 110(4): 243-7[PubMed]
  • 15. Erem C, Kavgaci H, Ersoz HO, Hacihasanoglu A, Ukinc K, Karti SS, et al. Blood coagulation and fibrinolytic activity in hypothyroidism. Int J Clin Pract. 2003; 57(2): 78-81[PubMed]
  • 16. Marongiu F, Conti M, Mameli G, Murtas ML, Balzano S, Sorano G, et al. Fibrinogen and fibrinolytic activity in hyperthyroidism before and after antithyroid treatment. J Endocrinol Invest. 1988; 11(10): 723-5[DOI][PubMed]
  • 17. Marongiu F, Biondi G, Conti M, Murtas ML, Mameli G, Sorano GG, et al. Is a hypercoagulable state present in hypothyroidism? Thromb Haemost. 1992; 67(6): 729[PubMed]
  • 18. Chadarevian R, Bruckert E, Leenhardt L, Giral P, Ankri A, Turpin G. Components of the fibrinolytic system are differently altered in moderate and severe hypothyroidism. J Clin Endocrinol Metab. 2001; 86(2): 732-7[DOI][PubMed]
  • 19. Horne M3, Singh KK, Rosenfeld KG, Wesley R, Skarulis MC, Merryman PK, et al. Is thyroid hormone suppression therapy prothrombotic? J Clin Endocrinol Metab. 2004; 89(9): 4469-73[DOI][PubMed]
  • 20. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). J Clin Endocrinol Metab. 2002; 87(2): 489-99[DOI][PubMed]
  • 21. McQuade C, Skugor M, Brennan DM, Hoar B, Stevenson C, Hoogwerf BJ. Hypothyroidism and moderate subclinical hypothyroidism are associated with increased all-cause mortality independent of coronary heart disease risk factors: a PreCIS database study. Thyroid. 2011; 21(8): 837-43[DOI][PubMed]
  • 22. Ichiki T. Thyroid hormone and atherosclerosis. Vascul Pharmacol. 2010; 52(3-4): 151-6[DOI][PubMed]
  • 23. Frostegard J. Atherosclerosis in patients with autoimmune disorders. Arterioscler Thromb Vasc Biol. 2005; 25(9): 1776-85[DOI][PubMed]
  • 24. Squizzato A, Romualdi E, Buller HR, Gerdes VE. Clinical review: Thyroid dysfunction and effects on coagulation and fibrinolysis: a systematic review. J Clin Endocrinol Metab. 2007; 92(7): 2415-20[DOI][PubMed]
  • 25. Egeberg O. Thyroid Function and Hemostasis. Scand J Clin Lab Invest. 1964; 16: 511-2[PubMed]
  • 26. Simone JV, Abildgaard CF, Schulman I. Blood coagulation in thyroid dysfunction. N Engl J Med. 1965; 273(20): 1057-61[DOI][PubMed]
  • 27. Hume R. Fibrinolytic Activity and Thyroid Function. Br Med J. 1965; 1(5436): 686-8[PubMed]
  • 28. Bennett NB, Ogston CM, McAndrew GM. The thyroid and fibrinolysis. Br Med J. 1967; 4(5572): 147-8[PubMed]
  • 29. Rennie JA, Bewsher PD, Murchison LE, Ogston D. Coagulation and fibrinolysis in thyroid disease. Acta Haematol. 1978; 59(3): 171-7[PubMed]
  • 30. Akinci B, Comlekci A, Ozcan MA. The alteration of coagulation in patients with thyroid dysfunction. Recent Pat Endocr Metab Immune Drug Discov. 2011; 5(1): 50-7[PubMed]
  • 31. Gazdag A, Nagy EV, Burman KD, Paragh G, Jenei Z. Improved endothelial function and lipid profile compensate for impaired hemostatic and inflammatory status in iatrogenic chronic subclinical hyperthyroidism of thyroid cancer patients on L-t4 therapy. Exp Clin Endocrinol Diabetes. 2010; 118(6): 381-7[DOI][PubMed]
  • 32. Federici AB. Acquired von Willebrand syndrome associated with hypothyroidism: a mild bleeding disorder to be further investigated. Semin Thromb Hemost. 2011; 37(1): 35-40[PubMed]
  • 33. Squizzato A, Romualdi E, Piantanida E, Gerdes VE, Buller HR, Tanda M, et al. Subclinical hypothyroidism and deep venous thrombosis. A pilot cross-sectional study. Thromb Haemost. 2007; 97(5): 803-6[PubMed]
  • 34. Stuijver DJ, Piantanida E, van Zaane B, Galli L, Romualdi E, Tanda ML, et al. Acquired von Willebrand syndrome in patients with overt hypothyroidism: a prospective cohort study. Haemophilia. 2014; 20(3): 326-32[DOI][PubMed]
  • 35. Mina A, Favaloro EJ, Koutts J. Hemostatic dysfunction associated with endocrine disorders as a major risk factor and cause of human morbidity and mortality: a comprehensive meta-review. Semin Thromb Hemost. 2007; 33(8): 798-809[DOI][PubMed]
  • 36. Sjoberg RJ, Kidd GS, Swanson EW, O'Barr TP, Corby DG, Hofeldt FD. Effects of hypothyroidism and short-term aging on whole blood thromboxane and arterial prostacyclin synthesis. J Lab Clin Med. 1987; 110(5): 576-82[PubMed]
  • 37. van Doormaal JJ, van der Meer J, Oosten HR, Halie MR, Doorenbos H. Hypothyroidism leads to more small-sized platelets in circulation. Thromb Haemost. 1987; 58(4): 964-5[PubMed]
  • 38. Gullu S, Sav H, Kamel N. Effects of levothyroxine treatment on biochemical and hemostasis parameters in patients with hypothyroidism. Eur J Endocrinol. 2005; 152(3): 355-61[DOI][PubMed]
  • 39. Endo Y. Relationship between thyroid function and platelet counts. Acta Haematol. 1985; 74(1): 58-9[PubMed]
  • 40. Oliveira MC, Kramer CK, Marroni CP, Leaes CGS, Viana L, Roithman S, et al. Acquired Factor VIII and von Willebrand Factor (aFVIII/VWF) Deficiency and Hypothyroidism in a Case With Hypopituitarism. Clin Appl Thrombos Hemostasis. 2010; 16(1): 107-9[DOI]
  • 41. Ford HC, Carter JM. Haemostasis in hypothyroidism. Postgrad Med J. 1990; 66(774): 280-4[PubMed]
  • 42. Homoncik M, Gessl A, Ferlitsch A, Jilma B, Vierhapper H. Altered platelet plug formation in hyperthyroidism and hypothyroidism. J Clin Endocrinol Metab. 2007; 92(8): 3006-12[DOI][PubMed]
  • 43. Rogers J2, Shane SR, Jencks FS. Factor VIII activity and thyroid function. Ann Intern Med. 1982; 97(5): 713-6[PubMed]
  • 44. Nagasaki T, Inaba M, Henmi Y, Kumeda Y, Ueda M, Tahara H, et al. Change in von Willebrand factor and carotid intima-media thickness in hypothyroid patients with normal thyroid function after levothyroxine replacement therapy. Eur J Endocrinol. 2004; 150(2): 125-31[PubMed]
  • 45. Nagasaki T, Inaba M, Kumeda Y, Ueda M, Hiura Y, Tahara H, et al. Decrease of arterial stiffness at common carotid artery in hypothyroid patients by normalization of thyroid function. Biomed Pharmacother. 2005; 59(1-2): 8-14[DOI][PubMed]
  • 46. Yango J, Alexopoulou O, Eeckhoudt S, Hermans C, Daumerie C. Evaluation of the respective influence of thyroid hormones and TSH on blood coagulation parameters after total thyroidectomy. Eur J Endocrinol. 2011; 164(4): 599-603[DOI][PubMed]
  • 47. Arnaout MA, Awidi AS, el-Najdawi AM, Khateeb MS, Ajlouni KM. Arginine-vasopressin and endothelium-associated proteins in thyroid disease. Acta Endocrinol (Copenh). 1992; 126(5): 399-403[PubMed]
  • 48. Stuijver DJ, Hooper JM, Orme SM, Van Zaane B, Squizzato A, Piantanida E, et al. Fibrin clot structure and fibrinolysis in hypothyroid individuals: the effects of normalising thyroid hormone levels. J Thromb Haemost. 2012; 10(8): 1708-10[DOI][PubMed]
  • 49. Ajjan R, Lim BC, Standeven KF, Harrand R, Dolling S, Phoenix F, et al. Common variation in the C-terminal region of the fibrinogen beta-chain: effects on fibrin structure, fibrinolysis and clot rigidity. Blood. 2008; 111(2): 643-50[DOI][PubMed]
  • 50. Alturfan AA, Alturfan EE, Dariyerli N, Zengin E, Aytac E, Yigit G, et al. Investigation of tissue factor and other hemostatic profiles in experimental hypothyroidism. Endocrine. 2006; 30(1): 63-7[DOI][PubMed]
  • 51. van Oosterom AT, Mattie H, Hermens WT, Veltkamp JJ. The influence of the thyroid function on the metabolic rate of prothrombin, factor VII, and factor X in the rat. Thromb Haemost. 1976; 35(3): 607-19[PubMed]
  • 52. Danescu LG, Badshah A, Danescu SC, Janjua M, Marandici AM, Matta F, et al. Venous thromboembolism in patients hospitalized with thyroid dysfunction. Clin Appl Thromb Hemost. 2009; 15(6): 676-80[DOI][PubMed]
  • 53. Ramagopalan SV, Wotton CJ, Handel AE, Yeates D, Goldacre MJ. Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study. BMC Med. 2011; 9: 1[DOI][PubMed]
  • 54. Peralta AR, Canhao P. Hypothyroidism and cerebral vein thrombosis--a possible association. J Neurol. 2008; 255(7): 962-6[DOI][PubMed]
  • 55. Farid NR, Griffiths BL, Collins JR, Marshall WH, Ingram DW. Blood coagulation and fibrinolysis in thyroid disease. Thromb Haemost. 1976; 35(2): 415-22[PubMed]
  • 56. Chadarevian R, Bruckert E, Ankri A, Beucler I, Giral P, Turpin G. Relationship between thyroid hormones and plasma D-dimer levels. Thromb Haemost. 1998; 79(1): 99-103[PubMed]
  • 57. Thomas DP, Roberts HR. Hypercoagulability in venous and arterial thrombosis. Ann Intern Med. 1997; 126(8): 638-44[PubMed]
  • 58. Chadarevian R, Bruckert E, Giral P, Turpin G. Relationship between thyroid hormones and fibrinogen levels. Blood Coagul Fibrinolysis. 1999; 10(8): 481-6[PubMed]
  • 59. Verkleij CJ, Stuijver DJ, van Zaane B, Squizzato A, Brandjes DP, Buller HR, et al. Thrombin-activatable fibrinolysis inhibitor in hypothyroidism and hyperthyroxinaemia. Thromb Haemost. 2013; 109(2): 214-20[DOI][PubMed]
  • 60. Cesarman-Maus G, Hajjar KA. Molecular mechanisms of fibrinolysis. Br J Haematol. 2005; 129(3): 307-21[DOI][PubMed]
  • 61. Bouma BN, Mosnier LO. Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis. Pathophysiol Haemost Thromb. 2003; 33(5-6): 375-81[PubMed]
  • 62. Ermantas N, Guldiken S, Demir M, Tugrul A. Thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and activity assay in patients with primary hypothyroidism. Clin Appl Thromb Hemost. 2010; 16(5): 568-73[DOI][PubMed]
  • 63. Guven GS, Kilicaslan A, Oz SG, Haznedaroglu IC, Kirazli S, Aslan D, et al. Decrements in the thrombin activatable fibrinolysis inhibitor (TAFI) levels in association with orlistat treatment in obesity. Clin Appl Thromb Hemost. 2006; 12(3): 364-8[DOI][PubMed]
  • 64. Kitagawa N, Yano Y, Gabazza EC, Bruno NE, Araki R, Matsumoto K, et al. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients. Diabetes Res Clin Pract. 2006; 73(2): 150-7[DOI][PubMed]
  • 65. Akinci B, Comlekci A, Ali Ozcan M, Demir T, Yener S, Demirkan F, et al. Elevated thrombin activatable fibrinolysis inhibitor (TAFI) antigen levels in overt and subclinical hypothyroid patients were reduced by levothyroxine replacement. Endocr J. 2007; 54(1): 45-52[PubMed]
  • 66. Erem C, Ucuncu O, Yilmaz M, Kocak M, Nuhoglu I, Ersoz HO. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor in patients with hypothyroidism. Endocrine. 2009; 35(1): 75-80[DOI][PubMed]
  • 67. Cetinkalp S, Tobu M, Karadeniz M, Buyukkececi F, Yilmaz C. The effect of hormone replacement treatment on thrombin-activatable fibrinolysis inhibitor activity levels in patients with Hashimoto thyroiditis. Intern Med. 2009; 48(5): 281-5[PubMed]
  • 68. Alioglu B, Kilic N, Simsek E, Dallar Y. Increased thrombin-activatable fibrinolysis inhibitor and decreased tissue factor pathway inhibitor and thrombomodulin levels in children with hypothyroidism. J Clin Res Pediatr Endocrinol. 2012; 4(3): 146-50[DOI][PubMed]
  • 69. Muller B, Tsakiris DA, Roth CB, Guglielmetti M, Staub JJ, Marbet GA. Haemostatic profile in hypothyroidism as potential risk factor for vascular or thrombotic disease. Eur J Clin Invest. 2001; 31(2): 131-7[PubMed]
  • 70. Dorr M, Robinson DM, Wallaschofski H, Schwahn C, John U, Felix SB, et al. Low serum thyrotropin is associated with high plasma fibrinogen. J Clin Endocrinol Metab. 2006; 91(2): 530-4[DOI][PubMed]
  • 71. Mohamed-Ali MS, Ahmed RO. Coagulation profiles in hypothyroid and hyperthyroid female patients in Sudan. Saudi Med J. 2008; 29(9): 1289-93[PubMed]
  • 72. Gursoy A, Ozduman Cin M, Kamel N, Gullu S. Which thyroid-stimulating hormone level should be sought in hypothyroid patients under L-thyroxine replacement therapy? Int J Clin Pract. 2006; 60(6): 655-9[DOI][PubMed]
  • 73. Negrev NN, Radev RZ, Velikova MS, Anogeianaki A. Effects of the hormones of the thyroid axis on the vitamin K-dependent plasma factors of blood coagulation (II, VII, IX, and X). Int J Immunopathol Pharmacol. 2008; 21(1): 221-6[DOI][PubMed]
  • 74. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000; 283(15): 2008-12[PubMed]
  • 75. Franchini M, Montagnana M, Manzato F, Vescovi PP. Thyroid dysfunction and hemostasis: an issue still unresolved. Semin Thromb Hemost. 2009; 35(3): 288-94[DOI][PubMed]
  • 76. Dalton RG, Dewar MS, Savidge GF, Kernoff PB, Matthews KB, Greaves M, et al. Hypothyroidism as a cause of acquired von Willebrand's disease. Lancet. 1987; 1(8540): 1007-9[PubMed]
  • 77. Erem C. Blood coagulation, fibrinolytic activity and lipid profile in subclinical thyroid disease: subclinical hyperthyroidism increases plasma factor X activity. Clin Endocrinol (Oxf). 2006; 64(3): 323-9[DOI][PubMed]
  • 78. Kvetny J, Heldgaard PE, Bladbjerg EM, Gram J. Subclinical hypothyroidism is associated with a low-grade inflammation, increased triglyceride levels and predicts cardiovascular disease in males below 50 years. Clin Endocrinol (Oxf). 2004; 61(2): 232-8[DOI][PubMed]
  • 79. Lowe GD. Arterial disease and venous thrombosis: are they related, and if so, what should we do about it? J Thromb Haemost. 2006; 4(9): 1882-5[DOI][PubMed]
  • 80. Agnelli G, Becattini C. Venous thromboembolism and atherosclerosis: common denominators or different diseases? J Thromb Haemost. 2006; 4(9): 1886-90[DOI][PubMed]
  • 81. Hostiuc M, Curca GC, Dermengiu D, Sinescu C, Hostiuc S. Can subclinical hypothyroidism explain some sudden deaths due to pulmonary embolism without evident risk factors? Med Hypotheses. 2011; 76(6): 855-7[DOI][PubMed]
  • 82. Biondi B, Cooper DS. The clinical significance of subclinical thyroid dysfunction. Endocr Rev. 2008; 29(1): 76-131[DOI][PubMed]
  • 83. Tian L, Ni J, Guo T, Liu J, Dang Y, Guo Q, et al. TSH stimulates the proliferation of vascular smooth muscle cells. Endocrine. 2014; 46(3): 651-8[DOI][PubMed]
  • 84. Duntas LH, Wartofsky L. Cardiovascular risk and subclinical hypothyroidism: focus on lipids and new emerging risk factors. What is the evidence? Thyroid. 2007; 17(11): 1075-84[DOI][PubMed]
  • 85. Aggarwal S, Sharma N. Cerebral venous sinus thrombosis with autoimmune thyroiditis. Indian J Endocrinol Metab. 2013; 17-7[DOI][PubMed]
  • 86. Canturk Z, Cetinarslan B, Tarkun I, Canturk NZ, Ozden M, Duman C. Hemostatic system as a risk factor for cardiovascular disease in women with subclinical hypothyroidism. Thyroid. 2003; 13(10): 971-7[DOI][PubMed]
  • 87. Squizzato A, Galli L, van Zaane B, Romualdi E, Stuijver DJ, Dentali F, et al. The effect of subclinical hypothyroidism on vitamin K antagonist treatment. Thromb Res. 2012; 129(4): 520-2[DOI][PubMed]
  • 88. Dorr M, Empen K, Robinson DM, Wallaschofski H, Felix SB, Volzke H. The association of thyroid function with carotid artery plaque burden and strokes in a population-based sample from a previously iodine-deficient area. Eur J Endocrinol. 2008; 159(2): 145-52[DOI][PubMed]
  • 89. Guldiken S, Demir M, Turgut B, Altun BU, Arikan E, Kara M. Global fibrinolytic capacity in patients with subclinical hypothyroidism. Endocr J. 2005; 52(3): 363-7[PubMed]
  • 90. Erden S, Buyukozturk S, Vural P, Degirmencioglu S. Acute-phase reactans in Hashimoto thyroiditis. Int Immunopharmacol. 2008; 8(13-14): 1863-5[DOI][PubMed]
  • 91. Marongiu F, Conti M, Murtas ML, Mameli G, Sorano GG, Martino E. Activation of blood coagulation and fibrinolysis in Graves' disease. Horm Metab Res. 1991; 23(12): 609-11[DOI][PubMed]
  • 92. Jorde R, Figenschau Y, Hansen JB. Haemostatic function in subjects with mild subclinical hypothyroidism. The Tromso study. Thromb Haemost. 2006; 95(4): 750-1[PubMed]
  • 93. Ochs N, Auer R, Bauer DC, Nanchen D, Gussekloo J, Cornuz J, et al. Meta-analysis: subclinical thyroid dysfunction and the risk for coronary heart disease and mortality. Ann Intern Med. 2008; 148(11): 832-45[PubMed]
  • 94. Karch A, Thomas SL. Autoimmune thyroiditis as a risk factor for stroke: a historical cohort study. Neurology. 2014; 82(18): 1643-52[DOI][PubMed]
  • 95. Marongiu F, Conti M, Murtas ML, Sorano GG, Mameli G, Salis G, et al. Anticardiolipin antibodies in Grave's disease: relationship with thrombin activity in vivo. Thromb Res. 1991; 64(6): 745-9[PubMed]
  • 96. Carlioglu A, Timur O, Durmaz SA, Ayhan ME. Mean platelet volume in euthyroid patients with Hashimoto's thyroiditis. Blood Coagul Fibrinolysis. 2015; 26(3): 282-4[DOI][PubMed]
  • 97. Dentali F, Rancan E, van Zaane B, Gerdes VE, Venco A, Ageno W, et al. The effect of thyroid autoantibodies on warfarin stability. Thromb Res. 2010; 126(1)-2[DOI][PubMed]
  • 98. Zoller B, Li X, Sundquist J, Sundquist K. Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden. Lancet. 2012; 379(9812): 244-9[DOI][PubMed]
  • 99. Franchini M, Lippi G, Manzato F, Vescovi PP. Thyroid-associated autoimmune coagulation disorders. J Thromb Thrombolysis. 2010; 29(1): 87-91[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader

Cited By:

International Journal of Endocrinology and Metabolism accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check